The board of 3D Medicines Inc. has convened its annual general meeting (AGM) for 10:00 a.m. on 30 June 2026 at Building 3-6, 7 Liangshuihe 1st Street, Yizhuang Biomedical Park, Beijing.

Key resolutions to be put to shareholders are as follows:

1. Financial Statements • Adoption of the audited consolidated results for the year ended 31 December 2025, together with directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of Dr. Gong Zhaolong (executive director), Mr. Zhou Feng (non-executive director) and Ms. Chen Yawen (non-executive director). • Authorisation for the board to fix directors’ remuneration.

3. Auditor • Re-appointment of Modern Assure CPA Limited until the next AGM with board-determined fees.

4. Share Capital Mandates • General issuance mandate: authority for the board to allot and issue additional shares or convertible securities up to 20% of the company’s issued share capital, with an extension for shares repurchased under the buy-back mandate (see below). • Share buy-back mandate: authority to repurchase up to 10% of issued shares on the Hong Kong Stock Exchange or other recognised markets. • Extension mandate: if both the issuance and buy-back mandates are approved, the issuance limit can be increased by the number of shares bought back, subject to a cap of 10% of issued shares.

Shareholders’ register will be closed from 25 June 2026 to 30 June 2026 (both days inclusive). Transfers must be lodged by 4:30 p.m. on 24 June 2026 to qualify for AGM attendance and voting.

Voting on all resolutions will be conducted by poll.

As of the notice date (8 June 2026), the board comprises one executive director, three non-executive directors and three independent non-executive directors. Proxies must be lodged at Tricor Investor Services or via the designated e-voting platform at least 48 hours before the meeting.